| Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer O Saatci, A Kaymak, U Raza, PG Ersan, O Akbulut, CE Banister, ... Nature communications 11 (1), 2416, 2020 | 209 | 2020 |
| Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer RR Mishra, N Belder, SA Ansari, M Kayhan, H Bal, U Raza, PG Ersan, ... Clinical Cancer Research 24 (8), 1987-2001, 2018 | 47 | 2018 |
| Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer R Assidicky, UM Tokat, IO Tarman, O Saatci, PG Ersan, U Raza, H Ogul, ... Breast cancer research and treatment 193 (2), 331-348, 2022 | 22 | 2022 |
| TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice M Yildirim, TC Yildirim, N Turay, T Bildik, B Ibibik, I Evcili, PG Ersan, ... Immunology Letters 239, 32-41, 2021 | 16 | 2021 |
| HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin M Biondini, A Kiepas, L El-Houjeiri, MG Annis, BE Hsu, AM Fortier, ... Oncogene 41 (12), 1701-1717, 2022 | 12 | 2022 |
| Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview E Özgü, E Aydin, A Adibi, ÜM Tokat, O Tutar, J Hu, I Demiray, R Kurzrock, ... JCO Precision Oncology 7, e2300299, 2023 | 1 | 2023 |
| Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ... Nature Communications 14 (1), 6997, 2023 | 1 | 2023 |
| Abstract PO4-23-10: Restoring the efficacy of standard of care in treatment-refractory ER+ breast cancer by re-activation of cAMP-ROS-DNA damage axis O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ... Cancer Research 84 (9_Supplement), PO4-23-10-PO4-23-10, 2024 | | 2024 |
| Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib … E Aydın, ÜM Tokat, E Özgü, A Adibi, O Tutar, R Kurzrock, M Demiray Therapeutic Advances in Medical Oncology 16, 17588359241247023, 2024 | | 2024 |
| Targeting PDE4D reinstates toxic PARP trapping via cAMP-ROS-DNA damage axis and restores the efficacy of standard of care in treatment-refractory ER+ breast cancer O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, E Montaudon, ... Cancer Research 84 (6_Supplement), 563-563, 2024 | | 2024 |
| Abstract A008: Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ... Cancer Research 84 (1_Supplement), A008-A008, 2024 | | 2024 |
| PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview A Adibi, ÜM Tokat, E Özgü, E Aydın, İ Demiray, M Demiray Therapeutic Advances in Medical Oncology 15, 17588359231213841, 2023 | | 2023 |
| Evaluation of the Relationship between Aromatase/Sirtuin1 Interaction and miRNA Expression in Human Neuroblastoma Cells Y Kartal, UM Tokat, P Kelicen-Ugur, S Yılmaz, S Karahan, MT Budak Current Molecular Pharmacology 16 (6), 609-628, 2023 | | 2023 |
| Overcoming tamoxifen resistance by re-activating cAMP-Ca2+−ROS-ferroptosis axis in ER+ breast cancer R Alam, O Saatci, MB Uner, KT Huynh-Dam, M Cetin, ME Gedik, N Belder, ... Cancer Research 83 (7_Supplement), 3883-3883, 2023 | | 2023 |
| Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer O Saatci, R Alam, KT Huynh-Dam, A Isik, M Uner, N Belder, PG Ersan, ... bioRxiv, 2023.11. 05.565697, 2023 | | 2023 |
| Overcoming tamoxifen resistance and inhibiting metastatic recurrence in estrogen receptor-positive breast cancer PG Ersan, O Saatci, O Tarman, R Mishra, N Belder, UM Tokat, ... Cancer Research 79 (13_Supplement), 2121-2121, 2019 | | 2019 |
| Identifying and targeting competing endogenous RNA (ceRNAs) networks to inhibit lung metastasis in triple negative breast cancer P Ersan, U Tokat, E Eyupoglu, U Raza, Y Riazalhosseini, C Alkan, ... Cancer Research 77 (13_Supplement), 2848-2848, 2017 | | 2017 |
| Competing endogenous RNA (ceRNAs) interaction network regulating lung metastasis in triple negative breast cancer PG Ersan, UM Tokat, E Eyupoglu, U Raza, Y Riazalhosseini, C Alkan, ... | | 2017 |
Pelin Gülizar ErsanPostdoctoral Researcher, Biotech Research and Innovation Centre (BRIC), University of CopenhagenAdresse e-mail validée de bric.ku.dk
